×
Skip to content
ShareCafe

  • Home
  • Shares
  • Advice
  • Wealth
    • Wealth Home
    • Product Profiles
  • Property
  • Video
  • Contributors
  • Community
  • About us
  • Facebook
  • Twitter
  • YouTube
  • RSS
Main Menu

Biotechnology

Biotechnology / Markets / Shares

Turnaround in Place at Cochlear

February 19, 2021February 19, 2021 - by Glenn Dyer

Hearing implant maker, Cochlear is making a return to paying dividends after the impact of COVID, the pandemic and social distancing rules damaged its 2020 finances.

Read More
Biotechnology / Markets / Shares

COVID a Tonic For CSL, Sonic

February 18, 2021February 18, 2021 - by Glenn Dyer

COVID has been good news for two of Australia’s health giants – Sonic Healthcare and CSL which both revealed very strong double-digit profits on Thursday for the six months to December.

Read More
Biotechnology / Markets / Shares / Video

Noxopharm Study Finds its Drug Improves Prostate Cancer Survival Rates

February 11, 2021February 11, 2021 - by Staff Writers

Noxopharm (ASX:NOX) announced this week independent drug trial results that significantly extended the life of men with prostrate cancer. The company’s CEO Dr Graham Kelly tells us more.

Read More
Biotechnology / Funds / Markets / Technology

Robotics and A.I.: Defeating COVID-19

February 11, 2021February 11, 2021 - by BetaShares

Alex Cook from BetaShares examines the role robotics and A.I. have played not only in developing a vaccine but also in its distribution.

Read More
Biotechnology / Markets / Shares / Technology

Growth For ResMed Despite Challenges

February 2, 2021February 2, 2021 - by Eva Brocklehurst

Growth in masks and accessories has prevailed for ResMed despite pandemic-induced restrictions, although cycling the surge in ventilator sales from early 2020 will be a challenge.

Read More
Biotechnology / Shares

Antisense Therapeutics – Price Target Raised from $0.305 to $0.43

January 14, 2021January 14, 2021 - by Tim McGowen

Corporate Connect analyst Marc Sinatra has raised his target price on Antisense Therapeutics (ASX: ANP) to $0.43 after a phase II trial involving potential competitor Sarepta Therapeutics’ SRP-9001 gene therapy failed to demonstrate an improvement in clinical function.

Read More
Biotechnology / Shares / Video

Immutep: fighting the good fight

December 17, 2020 - by Tim McGowen

In this video, immunotherapy pioneer Immutep’s (ASX: IMM) CEO Marc Voigt speaks with Share Cafe’s Tim McGowen about the company’s operations, clinical trials and future developments.

Read More
Biotechnology / Funds / Shares / Video

What’s next for Antisense Therapeutics?

November 19, 2020November 20, 2020 - by Tim McGowen

Mark Diamond, CEO and Managing Director of Australian biotech company Antisense Therapeutics (ASX: ANP), discusses the firm’s latest goings-on with Share Cafe’s Tim McGowen.

Read More
Biotechnology / Markets

COVID-19 Sees Buffett Dive Into Pharma

November 18, 2020November 18, 2020 - by Glenn Dyer

With the COVID-19 pandemic dominating markets, politics, and everyday life, it’s no wonder that Warren Buffett has moved heavily into pharma and medical stocks in the quarterly latest fund manager filing with the US Securities and Exchange Commission.

Read More
Biotechnology / Funds / Markets

A potential turning point in the battle against COVID-19

November 11, 2020November 11, 2020 - by Janus Henderson Investors

Pfizer and BioNTech have announced preliminary data from a late-stage clinical trial for their COVID-19 vaccine candidate, and the results were better than expected. Matt Peron and Andy Acker from Janus Henderson Investors explain what this means for the fight to end the pandemic and the next leg of the market cycle.

Read More
Biotechnology / Funds / Shares

Australian Healthcare: 10 Years In 10 Charts

November 10, 2020November 13, 2020 - by Alphinity Investment Management

With Alphinity celebrating its 10th anniversary we have explored what has happened in the healthcare sector in the decade since Alphinity was first established. 

Read More
Biotechnology / Shares

Antisense Eyes A Golden Ticket In The US

October 7, 2020October 7, 2020 - by Tim Boreham

Two announcements from drug developer Antisense Therapeutics have raised hopes of an expedited path to market for its novel candidate to treat a genetic muscular disorder that affects only boys and is regressive, fatal, and poorly treated.

Read More
Biotechnology / Markets / Shares

Mesoblast, COVID-19 And Trump?

September 1, 2020September 1, 2020 - by Marc Sinatra

As an analyst who follows biopharma companies, I take an interest in the US Food and Drug Administration (FDA), while as an American/Australian, US politics, particularly, in the days of Trump, is also an interest. Then, there is an ASX-listed cellular therapy company called Mesoblast (ASX:MSB), which I have followed pretty much since it listed in 2004.

Read More
Biotechnology

Understanding Biotechs Starts With Understanding How Drugs Are Named?

June 17, 2020June 17, 2020 - by Marc Sinatra

Drugs and biologics often end up with multiple names as they travel through the development and commercialisation. It can all get very confusing and even more so after the therapeutic is on the market but turns out to have multiple different names across multiple different jurisdictions.

Read More
  • Fuelling a Closer Look at Hydrogen
  • The Bond Crash of 2021? Seven Things for Investors to Consider
  • Bumper Half for Harvey Norman Confirmed
  • Will the Energy Sector Evolve or Devolve?
  • Evening Report: ASX 200 hits 4-week low
  • Bad News Comes in Threes for Orica
  • Lunch Report: Biggest tumble in 5 months
  • Australia…One Hour In…ASX200 down 158 points

Subscribe to ShareCafe

The daily resource for hands-on investors. Market insights and investment ideas delivered free to your inbox.

Copyright 2020 Informed Investor Pty Ltd ABN 42 162 871 589. All rights reserved.
No portion of this website maybe reproduced, copied or in any way released without written permission.
Share Cafe is a Corporate Authorised Representative (001283561) of PacReef Asset Management Pty Ltd who holds an Australian Financial Services Licence (Number: 488045)

Terms of Service | Privacy Policy | Contact | Advertise

DOWNLOAD RESEARCH REPORT

And a Door Opens Wide

Antisense Therapeutics’ lead drug sits at the nexus of two areas of drug development that are starting to grow dramatically in importance. One relates to its mode of action and the other to the type of drug it is. Combine that with management who know the drug very well and strong results in a trial in a horrible disease afflicting children, and you have the basis for true value creation.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Car.


DOWNLOAD RESEARCH REPORT

Fit for tough times; prepared for coal’s upswing

Terracom has counter-cyclically placed itself in a position to improve efficiency and margins plus pursue organic mine growth. Cashflows will further swell once currently depressed coal prices rebound. These assets appear undervalued compared to our Base Case $0.27/share NPV valuation of TER. TER has upside on management’s record of delivering new projects from currently controlled development assets and/or by opportunistically securing acquisitions.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Key.

DOWNLOAD RESEARCH REPORT

A Laser-Like Focus on Adding Value

Since August 1st, Kazia Therapeutics has announced US Food & Drug Administration fast track status for one program & orphan drug and rare paediatric disease designation for another, while finishing the period by announcing a new trial for its cancer drug, paxalisib. Over the next nine months investors are likely to see six data readouts from five programs. How fast can a company go?

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Truck.